Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Colorectal Neoplasms 113Colonic Neoplasms 30Neoplasm Metastasis 28Rectal Neoplasms 27Neoplasms 27Carcinoma, Non-Small-Cell Lung 14Esophageal Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Pancreatic Neoplasms 9Head and Neck Neoplasms 9Lung Neoplasms 8Cholangiocarcinoma 7Carcinoma, Squamous Cell 6Breast Neoplasms 6Colorectal Cancer Metastatic 5Carcinoma 5Triple Negative Breast Neoplasms 4Recurrence 4Prostatic Neoplasms 4Ovarian Neoplasms 4Inflammatory Breast Neoplasms 3Gastrointestinal Neoplasms 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Kidney Neoplasms 2Glioma 2Fallopian Tube Neoplasms 2

Interventions

Gemcitabine 157Cisplatin 116pembrolizumab 80Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Cystectomy 40Docetaxel 38atezolizumab 33Magnetic Resonance Spectroscopy 31durvalumab 30Radiotherapy 29BCG Vaccine 26avelumab 24Specimen Handling 24Doxorubicin 23enfortumab vedotin 22Fluorouracil 20Cystoscopy 20Methotrexate 17Vinblastine 16Standard of Care 15Filgrastim 14Transurethral Resection of Bladder 13Sunitinib 13Ipilimumab 13vinflunine 125-aminolevulinic acid hexyl ester 12tremelimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Urinary Bladder Neoplasms × Panitumumab × Clear all
NCT01916109 2016-02-12

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
4 enrolled 6 charts
Genitourinary

Cone Dystrophy 3, Urinary Bladder Neoplasms

NCT01374789 2015-06-03

PURO

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2 Terminated
2 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡